
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6058603/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. Value in Health, 2022, 25, 582-594.	0.3	6
2	Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. Diabetes Research and Clinical Practice, 2022, 183, 109152.	2.8	2
3	Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial. JAMA Cardiology, 2022, 7, 140.	6.1	5
4	Patient preferences pertaining to treatment options for drug-resistant focal epilepsy. Epilepsy and Behavior, 2022, 127, 108529.	1.7	5
5	Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008797.	3.9	7
6	Behavioral cancer pain intervention using videoconferencing and a mobile application for medically underserved patients: Rationale, design, and methods of a prospective multisite randomized controlled trial. Contemporary Clinical Trials, 2021, 102, 106287.	1.8	7
7	Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. New England Journal of Medicine, 2021, 385, 203-216.	27.0	267
8	Impact of financial medication assistance on medication adherence: a systematic review. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 924-935.	0.9	9
9	Factors Influential in the Selection of Radiology Residents in the Post–Step 1 World: A Discrete Choice Experiment. Journal of the American College of Radiology, 2021, 18, 1572-1580.	1.8	9
10	Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer. BMC Cancer, 2021, 21, 824.	2.6	3
11	The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Gynecologic Oncology, 2021, 162, 440-446.	1.4	2
12	Rehabilitation Intervention in Older Patients With Acute HeartÂFailure WithÂPreserved Versus Reduced EjectionÂFraction. JACC: Heart Failure, 2021, 9, 747-757.	4.1	32
13	Quantifying Value of Hope. Value in Health, 2021, 24, 1511-1519.	0.3	13
14	EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. Cancer Treatment and Research Communications, 2021, 27, 100327.	1.7	1
15	A randomized feasibility pilot trial of a financial incentives intervention for dietary self-monitoring and weight loss in adults with obesity. Translational Behavioral Medicine, 2021, 11, 954-969.	2.4	4
16	Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy. Biology of Blood and Marrow Transplantation, 2020, 26, 568-580.	2.0	8
17	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care, 2020, 43, 374-381.	8.6	4
18	Are Videos or Text Better for Describing Attributes in Stated-Preference Surveys?. Patient, 2020, 13, 401-408.	2.7	15

#	Article	IF	CITATIONS
19	Patient Preferences for Surgical Treatment of Knee Osteoarthritis. Journal of Bone and Joint Surgery - Series A, 2020, 102, 2022-2031.	3.0	10
20	Patient preferences for ketamine-based antidepressant treatments in treatment-resistant depression: Results from a clinical trial and panel. Neurology Psychiatry and Brain Research, 2020, 37, 67-78.	2.0	8
21	Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study. Value in Health, 2020, 23, 1438-1443.	0.3	34
22	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes Care, 2020, 43, 2485-2492.	8.6	3
23	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 75, 2297-2308.	2.8	48
24	Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. Clinical Breast Cancer, 2020, 20, 487-494.e1.	2.4	1
25	The burden of nonâ€cardiac comorbidities and association with clinical outcomes in an acute heart failure trial–Âinsights from ASCENDâ€HF. European Journal of Heart Failure, 2020, 22, 1022-1031.	7.1	27
26	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. Gynecologic Oncology, 2020, 156, 561-567.	1.4	21
27	Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. Cancer, 2019, 125, 4399-4406.	4.1	16
28	A Beginner's Guide to Understanding Curative Therapies. Value in Health, 2019, 22, 619-620.	0.3	2
29	Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations. Value in Health, 2019, 22, 684-692.	0.3	7
30	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care, 2019, 42, 1075-1080.	8.6	15
31	Preferences of women with epithelial ovarian cancer for aspects of genetic testing. Gynecologic Oncology Research and Practice, 2019, 6, 1.	3.6	13
32	Pain Coping Skills Training for Patients Who Catastrophize About Pain Prior to Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2019, 101, 218-227.	3.0	66
33	Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. Circulation: Cardiovascular Interventions, 2019, 12, e008051.	3.9	14
34	Use of clinical algorithms and rapid influenza testing to manage influenza-like illness: a cost-effectiveness analysis in Sri Lanka. BMJ Global Health, 2019, 4, e001291.	4.7	6
35	Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). Contemporary Clinical Trials, 2019, 76, 120-131.	1.8	12
36	The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments. Value in Health, 2019, 22, 157-160.	0.3	124

#	Article	IF	CITATIONS
37	Log2Lose: Development and Lessons Learned From a Mobile Technology Weight Loss Intervention. JMIR MHealth and UHealth, 2019, 7, e11972.	3.7	13
38	Study protocol for Log2Lose: A feasibility randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity. Contemporary Clinical Trials, 2018, 65, 116-122.	1.8	5
39	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1732-1739.	4.4	5
40	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, Obesity and Metabolism, 2018, 20, 2379-2388.	4.4	29
41	Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers. Therapeutic Innovation and Regulatory Science, 2018, 52, 507-513.	1.6	8
42	Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART. Contemporary Clinical Trials, 2017, 57, 51-57.	1.8	27
43	What is clearance worth? Patients' stated risk tolerance for psoriasis treatments. Journal of Dermatological Treatment, 2017, 28, 709-715.	2.2	15
44	Developing the Value Proposition for Personalized Medicine. , 2017, , 327-342.		2
45	The economics of PCSK-9 inhibitors. American Heart Journal, 2017, 189, 200-201.	2.7	8
46	Preferences for Health Interventions: Improving Uptake, Adherence, and Efficiency. Patient, 2017, 10, 511-514.	2.7	34
47	Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. American Heart Journal, 2017, 185, 130-139.	2.7	71
48	Does the Implantable Cardioverter-Defibrillator Benefit VaryÂWith the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?. JACC: Clinical Electrophysiology, 2017, 3, 291-298.	3.2	30
49	Depression, quality of life, and medical resource utilization in sickle cell disease. Blood Advances, 2017, 1, 1983-1992.	5.2	66
50	Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. Journal of Oncology Practice, 2017, 13, e120-e129.	2.5	11
51	Patient Preferences for Features of Health Care Delivery Systems: A Discrete Choice Experiment. Health Services Research, 2016, 51, 704-727.	2.0	29
52	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. American Journal of Cardiology, 2016, 117, 946-951.	1.6	23
53	Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, 28-37.e2.	1.9	9
54	Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology, 2015, 1, 158.	7.1	55

SHELBY D REED

#	Article	IF	CITATIONS
55	Staphylococcus aureus infections following knee and hip prosthesis insertion procedures. Antimicrobial Resistance and Infection Control, 2015, 4, 13.	4.1	20
56	Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report. Value in Health, 2015, 18, 161-172.	0.3	539
57	Implementing Lung Cancer Screening Using Low-Dose Computed Tomography: Recommendations From an Expert Panel. Journal of Oncology Practice, 2015, 11, e44-e49.	2.5	14
58	Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer. Journal of Palliative Medicine, 2015, 18, 933-939.	1.1	8
59	Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology, 2015, 1, 1098.	7.1	49
60	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. American Heart Journal, 2015, 170, 951-960.	2.7	7
61	Out-of-Pocket Spending for Ambulatory Physical Therapy Services From 2008 to 2012: National Panel Survey. Physical Therapy, 2015, 95, 1680-1691.	2.4	8
62	Patient preferences in advanced or recurrent ovarian cancer. Cancer, 2014, 120, 3651-3659.	4.1	68
63	Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. Pharmacogenomics, 2014, 15, 1677-1686.	1.3	30
64	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. JACC: Heart Failure, 2014, 2, 159-165.	4.1	91
65	Statistical considerations in economic evaluations: a guide for cardiologists. European Heart Journal, 2014, 35, 1652-1656.	2.2	11
66	Will the Future of Health Care Lead to the End of the Robotic Golden Years?. European Urology, 2014, 65, 325-327.	1.9	12
67	Associations Between Seattle Heart Failure Model Scores and Medical Resource Use and Costs: Findings From HF-ACTION. Journal of Cardiac Failure, 2014, 20, 541-547.	1.7	5
68	A Framework to Evaluate the Cost-Effectiveness of the NADiA ProsVue Slope to Guide Adjuvant Radiotherapy among Men with High-Risk Characteristics Following Prostatectomy for Prostate Cancer. Value in Health, 2014, 17, 545-554.	0.3	9
69	Update on the Role of Epothilones in Metastatic Breast Cancer. Current Breast Cancer Reports, 2013, 5, 51-56.	1.0	2
70	Associations Between Seattle Heart Failure Model Scores andÂHealth Utilities: Findings From HF-ACTION. Journal of Cardiac Failure, 2013, 19, 311-316.	1.7	15
71	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. JACC: Heart Failure, 2013, 1, 523-530.	4.1	22
72	Medical Resource Use, Costs, and Quality of Life in Patients With Acute Decompensated Heart Failure: Findings From ASCEND-HF. Journal of Cardiac Failure, 2013, 19, 611-620.	1.7	12

#	Article	IF	CITATIONS
73	Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genetics in Medicine, 2013, 15, 203-211.	2.4	44
74	Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 113-119.	2.2	17
75	Associations Between Hemoglobin Level, Resource Use, and Medical Costs in Patients With Heart Failure: Findings From HF-ACTION. Journal of Cardiac Failure, 2012, 18, 784-791.	1.7	5
76	Changes in Initial Treatment for Prostate Cancer Among Medicare Beneficiaries, 1999–2007. International Journal of Radiation Oncology Biology Physics, 2012, 82, e781-e786.	0.8	41
77	A phase III randomized three-arm trial of physical therapist delivered pain coping skills training for patients with total knee arthroplasty: the KASTPain protocol. BMC Musculoskeletal Disorders, 2012, 13, 149.	1.9	37
78	In-Hospital Resource Use and Medical Costs in the Last Year of Life by Mode of Death (from the) Tj ETQq0 0 0 r	gBT /Qverlo 1.6	ock 10 Tf 50 5
79	Effects of Family History and Genetic Polymorphism on the Cost-Effectiveness of Chemoprevention With Finasteride for Prostate Cancer. Journal of Urology, 2011, 185, 841-847.	0.4	12
80	End Point Selection in Acute Decompensated Heart Failure Clinical Trials: Economic End Points. Heart Failure Clinics, 2011, 7, 529-537.	2.1	0
81	Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement. American Journal of Hematology, 2010, 85, 79-81.	4.1	11
82	Economic Evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of) Tj ETQq0 C 2010, 3, 374-381.	0 rgBT /O 2.2	verlock 10 Tf 46
83	Economic Evaluation of Home Blood Pressure Monitoring With or Without Telephonic Behavioral Self-Management in Patients With Hypertension. American Journal of Hypertension, 2010, 23, 142-148.	2.0	52
84	Resource Use and Expenditures Among Adult Sickle Cell Patients with and without Depression. Blood, 2010, 116, 1534-1534.	1.4	3
85	Outcomes of inpatients with and without sickle cell disease after highâ€volume surgical procedures. American Journal of Hematology, 2009, 84, 703-709.	4.1	26
86	Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report. Value in Health, 2009, 12, 409-418.	0.3	395
87	Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer. Value in Health, 2009, 12, 637-640.	0.3	4
88	Resource Use and Costs of Treatment With Anticoagulation and Antiplatelet Agents: Results of the WATCH Trial Economic Evaluation. Journal of Cardiac Failure, 2009, 15, 819-827.	1.7	3
89	Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. Journal of Clinical Oncology, 2009, 27, 2185-2191.	1.6	38
90	Two self-management interventions to improve hypertension control: a randomized trial. Annals of Internal Medicine, 2009, 151, 687-95.	3.9	191

SHELBY D REED

#	Article	IF	CITATIONS
91	In-Hospital Outcomes Among Sickle Cell Patients with Acute Chest Syndrome: Results From a National Database Blood, 2009, 114, 1367-1367.	1.4	0
92	Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices. Journal of General Internal Medicine, 2008, 23, 50-56.	2.6	20
93	Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-?? Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. Pharmacoeconomics, 2008, 26, 435-446.	3.3	38
94	Is There a Price to Pay for Short-Term Savings in the Clinical Development of New Pharmaceutical Products?. Drug Information Journal, 2007, 41, 491-499.	0.5	1
95	Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia. Pharmacoeconomics, 2006, 24, 479-494.	3.3	12
96	Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal, 2006, 152, 500-508.	2.7	10
97	How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation. Health Affairs, 2006, 25, 1309-1317.	5.2	13
98	Economic Evaluation of Zoledronic Acid Versus Pamidronate for the Prevention of Skeletal-Related Events in Metastatic Breast Cancer and Multiple Myeloma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 8-16.	1.3	21
99	Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. Value in Health, 2005, 8, 521-533.	0.3	567
100	Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. Clinical Transplantation, 2005, 19, 122-129.	1.6	9
101	Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. Current Medical Research and Opinion, 2005, 21, 1527-1533.	1.9	13
102	Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal, 2005, 150, 323-329.	2.7	23
103	Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. American Heart Journal, 2005, 149, 434-443.	2.7	82
104	Long-term survival estimates for imatinib versus interferon-? plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004, 101, 2584-2592.	4.1	35
105	Cost-effectiveness of imatinib versus interferon-? plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004, 101, 2574-2583.	4.1	72
106	The Economic Burden of Allergic Rhinitis. Pharmacoeconomics, 2004, 22, 345-361.	3.3	182
107	COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER. Journal of Urology, 2004, 171, 1537-1542.	0.4	58
108	Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal, 2004, 148, 122-128	2.7	44

#	Article	IF	CITATIONS
109	The Association of an Early Hemoglobin Response with Alternative Metrics to Evaluate Treatment Efficacy of Erythropoietic Agents Blood, 2004, 104, 234-234.	1.4	1
110	Direct costs of allergic rhinitis in the united states: Estimates from the 1996 medical expenditure panel survey. Journal of Allergy and Clinical Immunology, 2003, 111, 296-300.	2.9	89
111	COMPARISON OF HOSPITAL COSTING METHODS IN AN ECONOMIC EVALUATION OF A MULTINATIONAL CLINICAL TRIAL. International Journal of Technology Assessment in Health Care, 2003, 19, 396-406.	0.5	27
112	Economic Issues and Antibiotic Resistance in the Community. Annals of Pharmacotherapy, 2002, 36, 148-154.	1.9	18
113	Difficulties in applying clinical trial information to the practice setting: Case of a high-cost drug. American Journal of Health-System Pharmacy, 1998, 55, 2409-2414.	1.0	1